Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCepsilon) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCepsilon activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts.
Molecular Weight:
843.98
Purity:
97.09%
CAS Number:
[182683-50-7]
Formula:
C37H65N9O13
Target:
PKC
T35827
T35827
* VAT and and shipping costs not included. Errors and price changes excepted
